세계의 거세저항성 전립선암 시장

Global Castrate-Resistant Prostate Cancer Market to Reach US$19.6 Billion by 2030

The global market for Castrate-Resistant Prostate Cancer estimated at US$12.6 Billion in the year 2024, is expected to reach US$19.6 Billion by 2030, growing at a CAGR of 7.7% over the analysis period 2024-2030. Hormonal Therapy, one of the segments analyzed in the report, is expected to record a 8.7% CAGR and reach US$10.2 Billion by the end of the analysis period. Growth in the Chemotherapy segment is estimated at 7.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.4 Billion While China is Forecast to Grow at 12.1% CAGR

The Castrate-Resistant Prostate Cancer market in the U.S. is estimated at US$3.4 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$4.2 Billion by the year 2030 trailing a CAGR of 12.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.8% and 7.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.1% CAGR.

Global Castrate-Resistant Prostate Cancer Market - Key Trends & Drivers Summarized

Why Is the Demand for Castrate-Resistant Prostate Cancer Treatment Increasing?

Castrate-resistant prostate cancer (CRPC) is an advanced form of prostate cancer that continues to progress despite androgen deprivation therapy (ADT). With prostate cancer being one of the most diagnosed cancers in men worldwide, the incidence of CRPC is steadily rising, necessitating the development of advanced treatment options. The increasing aging population, coupled with the growing prevalence of prostate cancer, is driving demand for innovative therapies that improve survival rates and enhance the quality of life for patients. Furthermore, advancements in early detection and diagnostics have contributed to more patients being diagnosed at an earlier stage, allowing for more effective treatment interventions. The introduction of liquid biopsies and next-generation sequencing technologies has enhanced precision medicine approaches, enabling personalized treatment regimens tailored to an individual’s genetic profile. As a result, pharmaceutical companies and research institutions are investing heavily in the development of novel therapeutics targeting CRPC.

How Are Emerging Therapies Revolutionizing CRPC Treatment?

The landscape of CRPC treatment has evolved significantly with the emergence of novel therapies, including next-generation androgen receptor inhibitors (ARIs), targeted radiopharmaceuticals, and immunotherapy. Drugs such as enzalutamide, abiraterone acetate, and apalutamide have revolutionized the treatment paradigm, offering improved survival benefits and delaying disease progression. These therapies work by targeting androgen signaling pathways, which remain active even in castration-resistant cases. Additionally, the development of radioligand therapies, such as lutetium-177 PSMA, has shown promising results in clinical trials by selectively targeting prostate-specific membrane antigen (PSMA)-expressing tumor cells. Immunotherapy, including checkpoint inhibitors and therapeutic cancer vaccines, is also gaining momentum, with ongoing trials exploring their efficacy in CRPC patients who exhibit resistance to conventional therapies. These innovations are significantly expanding the treatment arsenal for CRPC, offering patients new hope for extended survival and better disease management.

What Market Trends Are Driving the Adoption of CRPC Treatments?

Several key trends are influencing the CRPC market, including the shift toward combination therapies and the growing emphasis on personalized medicine. The increasing adoption of combination treatment strategies, which integrate androgen receptor inhibitors with chemotherapy or radiopharmaceuticals, has demonstrated superior clinical outcomes compared to monotherapy approaches. Pharmaceutical companies are focusing on multi-modal treatment regimens to enhance therapeutic efficacy and overcome drug resistance. Another significant trend is the integration of artificial intelligence (AI) and big data analytics in oncology research. AI-powered tools are being utilized to analyze vast datasets, identify biomarkers, and optimize treatment pathways for CRPC patients. This technological advancement is facilitating early diagnosis, aiding in patient stratification, and expediting drug discovery. Moreover, the expansion of telemedicine and remote patient monitoring solutions is improving access to specialist care, particularly for patients in remote and underserved regions.

What Are the Key Growth Drivers in the Castrate-Resistant Prostate Cancer Market?

The growth in the Castrate-Resistant Prostate Cancer market is driven by several factors, including the rising incidence of prostate cancer, advancements in targeted therapies, and increasing research investments in oncology drug development. The growing aging population, which is more susceptible to prostate cancer, is a significant factor contributing to market expansion. Additionally, regulatory support and expedited drug approvals by agencies such as the FDA and EMA are accelerating the introduction of innovative CRPC treatments. The rise of companion diagnostics and biomarker-driven treatment approaches is further enhancing therapeutic precision and patient outcomes. Furthermore, pharmaceutical companies are actively engaging in strategic collaborations and mergers to expand their oncology portfolios and gain a competitive edge in the rapidly evolving CRPC treatment landscape. As research efforts continue to push the boundaries of prostate cancer treatment, and as new therapeutics enter the market, the CRPC segment is poised for substantial growth, improving patient survival rates and transforming the standard of care for advanced prostate cancer worldwide.

SCOPE OF STUDY:

The report analyzes the Castrate-Resistant Prostate Cancer market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Therapy (Hormonal Therapy, Chemotherapy, Radiotherapy, Immunotherapy)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

• Arvinas, Inc.
• Astellas Pharma Inc.
• AstraZeneca plc
• Bayer AG
• Bayer Oy
• BeiGene, Ltd.
• Bristol Myers Squibb
• Clovis Oncology
• Daiichi Sankyo Company, Limited
• Dendreon Pharmaceuticals LLC
• ESSA Pharma Inc.
• GlaxoSmithKline plc
• Innocrin Pharmaceuticals
• Ipsen S.A.
• Johnson & Johnson
• Kintor Pharmaceutical Limited
• Myovant Sciences Ltd.
• Novartis International AG
• Noxopharm Limited
• Orion Corporation

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • Castrate-Resistant Prostate Cancer - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Global Incidence of Advanced Prostate Cancer Propels Demand for Castrate-Resistant Therapies
  • Technological Advancements in Biomarker Identification Strengthen Personalized Treatment Strategies
  • Growth in Immunotherapy and Targeted Therapy Approvals Expands Addressable Market Opportunity
  • Regulatory Fast-Track Approvals for Novel Agents Accelerate Market Entry and Patient Access
  • Expansion of Clinical Trials and Combination Therapies Throws Spotlight on Pipeline Innovation
  • Increasing Adoption of Androgen Receptor Pathway Inhibitors Drives Long-Term Treatment Outcomes
  • High Unmet Medical Needs in Late-Stage Patients Strengthen Business Case for Novel Drug Development
  • Rising Healthcare Expenditure in Oncology Sustains Market for Premium Therapeutics
  • Digital Health Integration and Remote Monitoring Enhance Patient Engagement and Compliance
  • Emergence of Liquid Biopsy Technologies Supports Early Detection of Therapy Resistance
  • Growing Focus on Quality of Life Outcomes Spurs Innovation in Low-Toxicity Treatment Regimens
  • Global Aging Population and Increased Screening Rates Sustain Demand for Advanced Therapies
  • Challenges in Drug Resistance and Disease Progression Propel Investment in Next-Generation Molecules
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Castrate-Resistant Prostate Cancer Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Castrate-Resistant Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Castrate-Resistant Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Castrate-Resistant Prostate Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Hormonal Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Hormonal Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Hormonal Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Radiotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Radiotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Radiotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Castrate-Resistant Prostate Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 17: USA Recent Past, Current & Future Analysis for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 18: USA Historic Review for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: USA 15-Year Perspective for Castrate-Resistant Prostate Cancer by Therapy - Percentage Breakdown of Value Sales for Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 20: Canada Recent Past, Current & Future Analysis for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 21: Canada Historic Review for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: Canada 15-Year Perspective for Castrate-Resistant Prostate Cancer by Therapy - Percentage Breakdown of Value Sales for Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy for the Years 2015, 2025 & 2030
• JAPAN
  • Castrate-Resistant Prostate Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 23: Japan Recent Past, Current & Future Analysis for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 24: Japan Historic Review for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: Japan 15-Year Perspective for Castrate-Resistant Prostate Cancer by Therapy - Percentage Breakdown of Value Sales for Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy for the Years 2015, 2025 & 2030
• CHINA
  • Castrate-Resistant Prostate Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 26: China Recent Past, Current & Future Analysis for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 27: China Historic Review for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: China 15-Year Perspective for Castrate-Resistant Prostate Cancer by Therapy - Percentage Breakdown of Value Sales for Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy for the Years 2015, 2025 & 2030
• EUROPE
  • Castrate-Resistant Prostate Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 29: Europe Recent Past, Current & Future Analysis for Castrate-Resistant Prostate Cancer by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: Europe Historic Review for Castrate-Resistant Prostate Cancer by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: Europe 15-Year Perspective for Castrate-Resistant Prostate Cancer by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 32: Europe Recent Past, Current & Future Analysis for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 33: Europe Historic Review for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: Europe 15-Year Perspective for Castrate-Resistant Prostate Cancer by Therapy - Percentage Breakdown of Value Sales for Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy for the Years 2015, 2025 & 2030
• FRANCE
  • Castrate-Resistant Prostate Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 35: France Recent Past, Current & Future Analysis for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 36: France Historic Review for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: France 15-Year Perspective for Castrate-Resistant Prostate Cancer by Therapy - Percentage Breakdown of Value Sales for Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy for the Years 2015, 2025 & 2030
• GERMANY
  • Castrate-Resistant Prostate Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 38: Germany Recent Past, Current & Future Analysis for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: Germany Historic Review for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: Germany 15-Year Perspective for Castrate-Resistant Prostate Cancer by Therapy - Percentage Breakdown of Value Sales for Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 41: Italy Recent Past, Current & Future Analysis for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: Italy Historic Review for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: Italy 15-Year Perspective for Castrate-Resistant Prostate Cancer by Therapy - Percentage Breakdown of Value Sales for Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Castrate-Resistant Prostate Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 44: UK Recent Past, Current & Future Analysis for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: UK Historic Review for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: UK 15-Year Perspective for Castrate-Resistant Prostate Cancer by Therapy - Percentage Breakdown of Value Sales for Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 47: Spain Recent Past, Current & Future Analysis for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Spain Historic Review for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: Spain 15-Year Perspective for Castrate-Resistant Prostate Cancer by Therapy - Percentage Breakdown of Value Sales for Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 50: Russia Recent Past, Current & Future Analysis for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Russia Historic Review for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: Russia 15-Year Perspective for Castrate-Resistant Prostate Cancer by Therapy - Percentage Breakdown of Value Sales for Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 53: Rest of Europe Recent Past, Current & Future Analysis for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Rest of Europe Historic Review for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: Rest of Europe 15-Year Perspective for Castrate-Resistant Prostate Cancer by Therapy - Percentage Breakdown of Value Sales for Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Castrate-Resistant Prostate Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Castrate-Resistant Prostate Cancer by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 57: Asia-Pacific Historic Review for Castrate-Resistant Prostate Cancer by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: Asia-Pacific 15-Year Perspective for Castrate-Resistant Prostate Cancer by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 59: Asia-Pacific Recent Past, Current & Future Analysis for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Asia-Pacific Historic Review for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Asia-Pacific 15-Year Perspective for Castrate-Resistant Prostate Cancer by Therapy - Percentage Breakdown of Value Sales for Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Castrate-Resistant Prostate Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 62: Australia Recent Past, Current & Future Analysis for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Australia Historic Review for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: Australia 15-Year Perspective for Castrate-Resistant Prostate Cancer by Therapy - Percentage Breakdown of Value Sales for Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy for the Years 2015, 2025 & 2030
• INDIA
  • Castrate-Resistant Prostate Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 65: India Recent Past, Current & Future Analysis for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: India Historic Review for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: India 15-Year Perspective for Castrate-Resistant Prostate Cancer by Therapy - Percentage Breakdown of Value Sales for Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 68: South Korea Recent Past, Current & Future Analysis for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: South Korea Historic Review for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: South Korea 15-Year Perspective for Castrate-Resistant Prostate Cancer by Therapy - Percentage Breakdown of Value Sales for Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 71: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Rest of Asia-Pacific Historic Review for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Rest of Asia-Pacific 15-Year Perspective for Castrate-Resistant Prostate Cancer by Therapy - Percentage Breakdown of Value Sales for Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Castrate-Resistant Prostate Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 74: Latin America Recent Past, Current & Future Analysis for Castrate-Resistant Prostate Cancer by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 75: Latin America Historic Review for Castrate-Resistant Prostate Cancer by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Latin America 15-Year Perspective for Castrate-Resistant Prostate Cancer by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 77: Latin America Recent Past, Current & Future Analysis for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Latin America Historic Review for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Latin America 15-Year Perspective for Castrate-Resistant Prostate Cancer by Therapy - Percentage Breakdown of Value Sales for Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 80: Argentina Recent Past, Current & Future Analysis for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Argentina Historic Review for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: Argentina 15-Year Perspective for Castrate-Resistant Prostate Cancer by Therapy - Percentage Breakdown of Value Sales for Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 83: Brazil Recent Past, Current & Future Analysis for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Brazil Historic Review for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: Brazil 15-Year Perspective for Castrate-Resistant Prostate Cancer by Therapy - Percentage Breakdown of Value Sales for Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 86: Mexico Recent Past, Current & Future Analysis for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Mexico Historic Review for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: Mexico 15-Year Perspective for Castrate-Resistant Prostate Cancer by Therapy - Percentage Breakdown of Value Sales for Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 89: Rest of Latin America Recent Past, Current & Future Analysis for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Rest of Latin America Historic Review for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: Rest of Latin America 15-Year Perspective for Castrate-Resistant Prostate Cancer by Therapy - Percentage Breakdown of Value Sales for Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Castrate-Resistant Prostate Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 92: Middle East Recent Past, Current & Future Analysis for Castrate-Resistant Prostate Cancer by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 93: Middle East Historic Review for Castrate-Resistant Prostate Cancer by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: Middle East 15-Year Perspective for Castrate-Resistant Prostate Cancer by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 95: Middle East Recent Past, Current & Future Analysis for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Middle East Historic Review for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Middle East 15-Year Perspective for Castrate-Resistant Prostate Cancer by Therapy - Percentage Breakdown of Value Sales for Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 98: Iran Recent Past, Current & Future Analysis for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Iran Historic Review for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Iran 15-Year Perspective for Castrate-Resistant Prostate Cancer by Therapy - Percentage Breakdown of Value Sales for Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 101: Israel Recent Past, Current & Future Analysis for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Israel Historic Review for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Israel 15-Year Perspective for Castrate-Resistant Prostate Cancer by Therapy - Percentage Breakdown of Value Sales for Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 104: Saudi Arabia Recent Past, Current & Future Analysis for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Saudi Arabia Historic Review for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Saudi Arabia 15-Year Perspective for Castrate-Resistant Prostate Cancer by Therapy - Percentage Breakdown of Value Sales for Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 107: UAE Recent Past, Current & Future Analysis for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: UAE Historic Review for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: UAE 15-Year Perspective for Castrate-Resistant Prostate Cancer by Therapy - Percentage Breakdown of Value Sales for Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 110: Rest of Middle East Recent Past, Current & Future Analysis for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Rest of Middle East Historic Review for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: Rest of Middle East 15-Year Perspective for Castrate-Resistant Prostate Cancer by Therapy - Percentage Breakdown of Value Sales for Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy for the Years 2015, 2025 & 2030
• AFRICA
  • Castrate-Resistant Prostate Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 113: Africa Recent Past, Current & Future Analysis for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Africa Historic Review for Castrate-Resistant Prostate Cancer by Therapy - Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: Africa 15-Year Perspective for Castrate-Resistant Prostate Cancer by Therapy - Percentage Breakdown of Value Sales for Hormonal Therapy, Chemotherapy, Radiotherapy and Immunotherapy for the Years 2015, 2025 & 2030

IV. COMPETITION